
Retinopathy: Golgi and Breye join forces
The two companies announced their collaboration, which aims to find treatment options for both early-stage diabetic retinopathy (DR) and dry-AMD...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....

Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

CEPI commits up to US$80m to University of Oxford to develop vaccines
The US$80m strategic partnership of CEPI, which was established in 2016 in the wake of the Ebola virus outbreak in west Africa, the University of...

Evotec earns US$40m in global licence deal with BMS
Under a potential US$4bn iPSC-based drug discovery partnership in neurodegeneration with Evotec SE, originally signed in 2016 through Celgene,...

Sygnature Discovery Ltd acquires leading Canadian CRO
The purchase of NuChem Sciences for an undisclosed sum is the third in a series of acquisitions in sixteen months as part of Sygnature's global...